AACR Annual Meeting
Mechanisms of action of a neoantigen-targeting antibody NEO-201 AACR Annual Meeting - March 30-April 4 2019...
30Mar
10Mar
Dr. Philip M Arlen to deliver to presentations on the NEO-201 program at the Molecular Med Tri-Con Meetings, March 10-15th, SF, CA
The Discovery and Development of Novel Monoclonal Antibody, NEO-201 Targeting a Novel Neoantigen Philip M. Arlen,...
01Nov
The National Cancer Institute Opens Clinical Trial Testing Safety and Dosing of NEO-201 Antibody in Patients with Advanced Cancer
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients...
16Apr
Precision Biologics along with Dr Christina Annunziata, MD, PhD, from the NCI are presenting at the AACR Annual Meeting
The neoantigen-targeting antibody NEO-201 enhances NK cell-dependent killing of tumor cells through blockade of the...
08Jan
Precision Biologics manuscript on our NEO-201 Antibody article published in Frontiers in Immunology
Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
08Jan
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments
Dr. Philip Arlen to Speak at Immunotherapy Progress and Clinical Treatments December 5-7, 2017 in San...
12Oct
Targeting cancer neoantigens: A promising source of immunogens for cancer immunotherapy
Dr. Philip Arlen to Speak at World Vaccine Congress Europe Topic: Targeting cancer neoantigens: A promising source...
17Aug
Dr. Philip Arlen to Speak at Immuno-Oncology Summit
Dr. Philip Arlen to Speak at Immuno-Oncology Summit - The Summit will return to Boston on...
05Jun
Dr. Philip Arlen to Speak at ASCO Annual Meeting
Dr. Philip Arlen to Speak at ASCO Annual Meeting - June 2-6, 2017 | McCormick Place...
19Apr
Read more...